Literature DB >> 6144692

Methodological aspects and clinical results of an assay for thyroid-stimulating antibodies: correlation with thyrotropin binding-inhibiting antibodies.

J Hensen, P Kotulla, R Finke, U Bogner, K Badenhoop, H Meinhold, H Schleusener.   

Abstract

Several methodological aspects concerning the measurement of thyroid-stimulating antibodies (TSAb) were examined using a 5000-g particulate fraction from human thyroid tissue. TSH displayed maximal stimulation at 32 C. An ATP-regenerating system had no influence at ATP concentrations greater than 0.67 mM. Theophylline did not influence cAMP concentrations in the incubation medium after stimulation with increasing dosages of TSH, suggesting the absence of active phosphodiesterases in the membrane preparations. Sera dialyzed against Tris-HCl were as suitable as immunoglobulin G preparations for determination of TSAb. One hundred and nineteen patients with ophthalmic Graves' disease, 42 of whom were hyperthyroid at the time of study, were investigated for TSH binding-inhibiting antibodies ( TBIAb ) and TSAb. In 76% of these patients, concordance between the presence and absence of both activities was found independent of whether they were untreated, treated, or in remission. When gradations of potency in the two systems were compared, linear regression revealed a correlation coefficient of 0.59. The coefficient correlation increased when TBIAb and TSAb were each determined in a single assay using identical thyroid membrane preparations. In four other patients, both TSAb and TBIAb were measured repeatedly during the course of the disease. In three patients, both activities were parallel, whereas in one patient, dissociation of the two activities was found. The data suggest the presence of antibodies with varying stimulating and binding-inhibiting properties. However, in hyperthyroidism of Graves' disease, both activities usually were present in similar quantities.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144692     DOI: 10.1210/jcem-58-6-980

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  The thyrotropin receptor and its role in Graves' disease.

Authors:  B Rees Smith; C R Rickards; E Davies Jones; Y Kajita; P R Buckland; F M Creagh; R D Howells; F Hashim; A B Parkes; V B Petersen
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

2.  Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.

Authors:  H Uchimura; N Akimoto; T Mitsuhashi; K Kubota; N Kuzuya; Y Imai; H Ikeda; F Matsuzaki; L F Kumagai
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

3.  Relationship between thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins years after administration of radioiodine for Graves' disease: retrospective clinical survey.

Authors:  K Yoshida; Y Aizawa; N Kaise; H Fukazawa; Y Kiso; N Sayama; K Mori; H Hori; K Abe
Journal:  J Endocrinol Invest       Date:  1996-11       Impact factor: 4.256

4.  Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.

Authors:  R Hörmann; B Saller; R Müller; K Mann
Journal:  Klin Wochenschr       Date:  1985-12-16

5.  Thyroid stimulating antibodies in rheumatoid arthritis: an in vitro phenomenon.

Authors:  C Kirkegaard; K Bech; H Bliddal; B Danneskiold-Samsoe; U Feldt-Rasmussen
Journal:  J Endocrinol Invest       Date:  1987-10       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.